Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$7.41 +3.6%	$6.70	$4.25 ▼ $9.85	$2.74B	0.41	2.67 million shs	2.19 million shs
GUD Knight Therapeutics	C$6.50 +1.6%	C$6.15	C$5.09 ▼ C$6.55	C$657.48M	0.5	66,509 shs	36,913 shs
THCX AXS Cannabis ETF	$16.60	$16.60	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A
TLRY Tilray Brands	$1.38 -6.1%	$0.74	$0.35 ▼ $1.88	$1.52B	1.85	42.69 million shs	50.53 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	-1.51%	-4.40%	+4.90%	+58.17%	+21.54%
GUD Knight Therapeutics	-1.39%	+0.47%	+4.23%	+11.11%	+15.73%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	0.00%	0.00%
TLRY Tilray Brands	+7.30%	+32.43%	+154.81%	+235.46%	-13.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.327 of 5 stars	2.0	4.0	0.0	4.0	2.8	3.3	1.9
GUD Knight Therapeutics	0.6878 of 5 stars	1.7	0.0	0.0	0.0	1.8	1.7	0.6
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	2.2143 of 5 stars	3.2	1.0	0.0	0.0	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.00	Hold	$9.00	21.46% Upside
GUD Knight Therapeutics	3.33	Buy	C$7.15	10.00% Upside
THCX AXS Cannabis ETF	2.58	Moderate Buy	$16.60	N/A
TLRY Tilray Brands	2.33	Hold	$1.94	40.40% Upside

Current Analyst Ratings Breakdown

Latest GUD, BHC, TLRY, and THCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/25/2025	TLRY Tilray Brands	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $2.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.28	$7.88 per share	0.94	$0.40 per share	18.53
GUD Knight Therapeutics	C$348.70M	1.89	C$1.69 per share	3.85	C$7.65 per share	0.85
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	$821.31M	1.85	$0.15 per share	9.48	$1.40 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	$0.26	28.50	1.59	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
GUD Knight Therapeutics	-C$30.73M	-C$0.30	N/A	∞	N/A	-8.81%	-4.04%	0.51%	N/A
THCX AXS Cannabis ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest GUD, BHC, TLRY, and THCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GUD Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	$0.72	4.34%	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	141.90	1.31	0.98
GUD Knight Therapeutics	7.52	3.36	1.79
THCX AXS Cannabis ETF	N/A	N/A	N/A
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
GUD Knight Therapeutics	12.58%
THCX AXS Cannabis ETF	N/A
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.05%
GUD Knight Therapeutics	45.62%
THCX AXS Cannabis ETF	N/A
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
GUD Knight Therapeutics	725	101.15 million	N/A	Not Optionable
THCX AXS Cannabis ETF	N/A	8.50 million	N/A	Not Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

GUD, BHC, TLRY, and THCX Headlines

Recent News About These Companies

Top Cannabis Stocks To Watch Now - August 28th

4 hours ago | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Shares Up 3.3% - Still a Buy?

4 hours ago | marketbeat.com

Pot Stocks Plunge After Rally: Is Betting on Rescheduling Worth the Risk?

August 29 at 11:47 AM | 247wallst.com

Tilray Brands (TLRY)’s Breckenridge Distillery Launches Mountain Shot

August 29 at 2:37 AM | finance.yahoo.com

Tilray Brands (NASDAQ:TLRY) Shares Down 5.9% - Should You Sell?

August 28 at 1:25 PM | marketbeat.com

Jefferies Raises Tilray (TLRY) Price Target on Potential Cannabis Rescheduling

August 28 at 8:10 AM | insidermonkey.com

Tilray Medical Expands Presence in Germany with Introduction of New Good Supply Medical Cannabis Strains

August 28 at 7:00 AM | globenewswire.com

Tilray Brands, Inc.: Tilray Brands Successfully Regains Compliance with Nasdaq's Minimum Bid Price Requirement

August 28 at 5:33 AM | finanznachrichten.de

Why Tilray (TLRY) Shares Are Plunging Today

August 28 at 5:33 AM | msn.com

Tilray Brands (NASDAQ:TLRY) Sees Unusually-High Trading Volume Following Analyst Upgrade

August 28 at 2:58 AM | americanbankingnews.com

Tilray Brands, Inc. (TLRY) Stock Falls Amid Market Uptick: What Investors Need to Know

August 27 at 7:00 PM | zacks.com

Tilray Brands Successfully Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

August 27 at 5:11 PM | financialpost.comF

Tilray Brands, Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement

August 27 at 5:11 PM | quiverquant.comQ

Tilray Brands Successfully Regains Compliance with Nasdaq's Minimum Bid Price Requirement

August 27 at 5:02 PM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Shares Up 3.2% on Analyst Upgrade

August 27 at 11:18 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Sees Strong Trading Volume After Analyst Upgrade

August 27 at 10:15 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Trading 3.2% Higher After Analyst Upgrade

August 27 at 2:29 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up on Analyst Upgrade

August 27 at 2:50 AM | americanbankingnews.com

Tilray: Sell The U.S. Rescheduling Rally

August 26 at 5:14 PM | seekingalpha.com

Why Tilray (TLRY) Stock Is Up Today

August 26 at 5:05 PM | msn.com

US cannabis stocks rally as Trump backs rescheduling

August 26 at 4:04 PM | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GUD, BHC, TLRY, and THCX Company Descriptions

Bausch Health Cos NYSE:BHC

$7.41 +0.26 (+3.64%)

Closing price 03:59 PM Eastern

Extended Trading

$7.41 0.00 (0.00%)

As of 04:45 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Knight Therapeutics TSE:GUD

C$6.50 +0.10 (+1.56%)

As of 04:00 PM Eastern

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)

As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

Tilray Brands NASDAQ:TLRY

$1.38 -0.09 (-6.12%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 05:42 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time